Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 3,311 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO John Cox sold 3,311 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total value of $60,789.96. Following the completion of the transaction, the chief executive officer directly owned 370,834 shares in the company, valued at $6,808,512.24. The trade was a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $18.28 on Friday. The stock has a market cap of $3.02 billion, a P/E ratio of -5.68 and a beta of 1.08. The stock has a 50 day simple moving average of $18.30 and a 200 day simple moving average of $18.64. The company has a current ratio of 19.92, a quick ratio of 22.25 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a 1-year low of $8.06 and a 1-year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the business earned ($1.05) earnings per share. Research analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Trending Headlines about Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $50 price target, while lifting several earnings forecasts for Dyne Therapeutics, signaling continued analyst confidence in the stock’s longer-term potential.
• Positive Sentiment: Lifesci Capital also increased its earnings estimates for 2026 and 2026 quarterly periods, reflecting improved expectations for Dyne Therapeutics’ financial outlook.
• Neutral Sentiment: Dyne Therapeutics said management will participate in upcoming investor conferences, which can help keep the company visible to shareholders but does not change the fundamentals by itself. Dyne Therapeutics to Participate in Upcoming Investor Conferences
• Neutral Sentiment: The company received an average brokerage rating of Moderate Buy, suggesting Wall Street sentiment remains constructive overall. Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Brokerages
• Negative Sentiment: CEO John Cox, CFO Erick Lucera, and insider Douglas Kerr each sold small blocks of stock, which can weigh on sentiment, although the filings say the sales were made to cover tax obligations tied to equity vesting.

Analysts Set New Price Targets

DYN has been the topic of a number of recent research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Chardan Capital restated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Sanford C. Bernstein lifted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday. Finally, Morgan Stanley cut their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.21.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. grew its holdings in shares of Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after purchasing an additional 14,727,667 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Dyne Therapeutics by 14.9% in the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after acquiring an additional 1,455,151 shares during the last quarter. State Street Corp boosted its holdings in shares of Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after acquiring an additional 1,423,828 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in Dyne Therapeutics by 45.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock worth $101,164,000 after acquiring an additional 1,618,000 shares during the last quarter. Finally, Orbis Allan Gray Ltd acquired a new position in Dyne Therapeutics in the 4th quarter worth about $93,926,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.